The clinical laboratory has adopted mouse monoclonal antibodies as a key component of basic research.
They are invaluable tools in many biological assays and remain the first choice in research. However, the traditional technology for hybridoma generation is slow, tedious, and low-throughput. You can know more about mouse monoclonal antibodies via https://www.bosterbio.com/services/custom-monoclonal-antibody-development-service.
Image Source: Google
Monoclonal antibody research has seen a revolution thanks to genetic immunization, automation, and microarray. We will be briefly reviewing the key strategies that have made it possible to manufacture murine monoclonal antibodies faster and more efficiently.
Monoclonal antibodies, which are well-known tools for studying the proteome, have wide applicability in biomedical sciences. These reagents have the unique characteristic of being high-specificity and sensitive binding reagents, making them excellent tools for basic research and for cancer diagnostics and treatment.
In the research field, they are used to detect proteins in cells in their native conformation (immune-localization), in the denatured form (western blot), or as high-affinity binders in immune-affinity-based assays.
Medical therapy, e.g. Monoclonal antibodies offer significant advantages over conventional chemical compound-based treatments for cancer and other infectious diseases.
They have favorable pharmacokinetics, pharmacotoxicity, and side effects, are specific and high affinity for the disease target and can recruit immune effectors to cause the destruction of target cells. Monoclonal antibody technology developed tremendously over the past 30 years.
Although there were later developments in monoclonal antibody production methods, such as recombinant DNA-based technology (Siegel 2002); expression in bacterial systems (Rader et. al. 1997); construction of phage display library (Rader et. al. 1997); and chimerization and humanization strategies that use transgenic animals (Lonberg and Al. 1994; the demand for large-scale monoclonal antibody manufacturing is continuously increasing.
This has led to a substantial implementation of traditional methods for monoclonal antibody screening and generation.